Oncolytics Biotech Trades Down 1.96 % Amid Volatile Market Conditions
Oncolytics Biotech Inc. (ONCY) experienced a decline of 1.96 % during the 24‑hour trading window that closed at 09:36 AM Central European Time on Friday, 23 March 2026. The stock, which is listed on the Toronto Stock Exchange, is currently priced at approximately USD 0.50 per share on major exchanges.
Market Snapshot
- Shares Outstanding: 131.1 million
- Market Capitalisation: USD 91.4 million
- Volume in Last 24 Hours: USD 202.8 k
- Year‑to‑Date Performance: -26.47 % since the close of the previous month
- 200‑Day Simple Moving Average: USD 0.88
- 52‑Week High: USD 1.32 (28 October 2025)
- 52‑Week Low: USD 0.44 (14 October 2026)
The recent dip aligns with a broader slide seen among several biotechnology and resource‑sector peers over the same period.
Comparative Performance of Related Stocks
| Stock | Recent Change | Current Price | Market Capitalisation |
|---|---|---|---|
| Engene Therapeutics (ENGN) | –2.4 % | USD 1.58 | USD 109.2 million |
| Platinum Metals (PTM.TO) | –9.04 % | CAD 1.51 | CAD 151.1 million |
| Healwell AI (AIDX.TO) | –1.45 % | CAD 0.68 | CAD 152.3 million |
| American Eagle Gold (AE.V) | –0.98 % | CAD 0.99 | CAD 152.4 million |
| Silver Mountain (AGMR.TO) | –4.91 % | CAD 2.96 | CAD 147.1 million |
These movements suggest a market‑wide pullback, particularly in the biotechnology and natural resources sectors.
Company Focus and Outlook
Oncolytics Biotech is a Canadian health‑care biotechnology firm dedicated to discovering and developing novel pharmaceuticals for cancers that have not responded to conventional therapies. Its flagship program involves the development of REOLYSIN, a reovirus platform that the company believes could become a transformative cancer therapeutic.
Founded in 1999, the company’s public offering was launched on November 8, 1999, and it remains listed on the Toronto Stock Exchange. For further details, including research updates and corporate announcements, visit the company’s website at www.oncolyticsbiotech.com .
The recent decline in ONCY’s share price reflects a combination of broader market volatility and sector‑specific concerns. Investors will likely monitor upcoming clinical data releases and regulatory milestones for REOLYSIN to gauge the company’s future trajectory.
